Literature DB >> 25827798

Inflammatory bowel disease pathogenesis: where are we?

Claudio Fiocchi1.   

Abstract

Inflammatory bowel disease (IBD) is presently one of the most investigated human disorders. Expansion of knowledge of its pathophysiology has helped in developing novel medications to combat gut inflammation with a considerably degree of success. Despite this progress, much more remains to be done in regard to gaining a more profound understanding of IBD pathogenesis, detecting inflammation before it clinically manifests, implementing lifestyle modifications, and developing agents that can modify the natural course of the disease. One of the limitations to achieve these goals is the lack of integration of the major components of IBD pathogenesis, that is the exposome, the genome, the gut microbiome, and the immunome. An "IBD integrome" approach that takes advantage of all functional information derived from the detailed investigation of each single pathogenic component through the use of systems biology may offer the solution to understand IBD and cure it.
© 2015 Journal of Gastroenterology and Hepatology Foundation and Wiley Publishing Asia Pty Ltd.

Entities:  

Keywords:  Crohn's disease; inflammatory bowel disease; integrome; pathogenesis; ulcerative colitis

Mesh:

Year:  2015        PMID: 25827798     DOI: 10.1111/jgh.12751

Source DB:  PubMed          Journal:  J Gastroenterol Hepatol        ISSN: 0815-9319            Impact factor:   4.029


  21 in total

1.  Postoperative Medical Management of Crohn's Disease: Prevention and Surveillance Strategies.

Authors:  Miguel Regueiro; Scott A Strong; Linda Ferrari; Alessandro Fichera
Journal:  J Gastrointest Surg       Date:  2016-05-26       Impact factor: 3.452

Review 2.  Living on Liquids: Surviving and Thriving on Exclusive Enteral Nutrition.

Authors:  Kelly Issokson
Journal:  Am J Gastroenterol       Date:  2017-09-05       Impact factor: 10.864

3.  Effect of Probiotic Use on Adverse Events in Adult Patients with Inflammatory Bowel Disease: a Retrospective Cohort Study.

Authors:  Maria Pina Dore; Chiara Rocchi; Nunzio Pio Longo; Antonio Mario Scanu; Gianpaolo Vidili; Federica Padedda; Giovanni Mario Pes
Journal:  Probiotics Antimicrob Proteins       Date:  2020-03       Impact factor: 4.609

Review 4.  Clinical Pharmacokinetics and Pharmacodynamics of Infliximab in the Treatment of Inflammatory Bowel Disease.

Authors:  Amy Hemperly; Niels Vande Casteele
Journal:  Clin Pharmacokinet       Date:  2018-08       Impact factor: 6.447

Review 5.  Advances in nutritional therapy in inflammatory bowel diseases: Review.

Authors:  Andrzej Wędrychowicz; Andrzej Zając; Przemysław Tomasik
Journal:  World J Gastroenterol       Date:  2016-01-21       Impact factor: 5.742

6.  Establishment and Development of the First Biobank of Inflammatory Bowel Disease, Suspected to Primary Immunodeficiency Diseases in Iran.

Authors:  Roya Sherkat; Soodabeh Rostami; Majid Yaran; Mohammad Hassan Emami; Hosein Saneian; Hamid Tavakoli; Peyman Adibi; Mahdieh Behnam; Saba Sheykhbahaei; Bahram Bagherpour; Razieh Khoshnevisan; Somayeh Najafi
Journal:  Adv Biomed Res       Date:  2018-03-27

7.  The Impact of Obesity on the Clinical Course of Inflammatory Bowel Disease: A Meta-Analysis.

Authors:  Qiongyuan Hu; Jianan Ren; Guanwei Li; Xiuwen Wu; Jieshou Li
Journal:  Med Sci Monit       Date:  2017-05-29

Review 8.  The Impact of Exclusive Enteral Nutrition (EEN) on the Gut Microbiome in Crohn's Disease: A Review.

Authors:  Amber MacLellan; Jessica Moore-Connors; Shannan Grant; Leah Cahill; Morgan G I Langille; Johan Van Limbergen
Journal:  Nutrients       Date:  2017-05-01       Impact factor: 5.717

9.  Ethyl Pyruvate: An Anti-Microbial Agent that Selectively Targets Pathobionts and Biofilms.

Authors:  Tewodros Debebe; Monika Krüger; Klaus Huse; Johannes Kacza; Katja Mühlberg; Brigitte König; Gerd Birkenmeier
Journal:  PLoS One       Date:  2016-09-22       Impact factor: 3.240

10.  Remote ischemic conditioning in active ulcerative colitis: An explorative randomized clinical trial.

Authors:  Line E Godskesen; Thomas R Lassen; Nichlas R Jespersen; Majken Siersbæk; Yan Yan; Michael M Nielsen; Sara K Tjønnfjord; Lars Grøntved; Gunvor Madsen; Jørgen Kjems; Hans E Bøtker; Michael R Schmidt; Aleksander Krag; Jens Kjeldsen
Journal:  Sci Rep       Date:  2020-06-12       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.